Abstract 2813: Survival benefit of an add-on dendritic cell vaccine for patients with inoperable pancreatic cancer receiving chemotherapy: a multicenter study

• Published in: Cancer research (Chicago, Ill.) Ill.), 2014-10, Vol.74 (19_Supplement), p.2813-2813
• Main Authors: Kobayashi, Masanori, Shigetaka, Shimodaira, Nagai, Kazuhiro, Ogasawara, Masahiro, Takahashi, Hidenori, Abe, Hirofumi, Tanii, Mitsugu, Okamoto, Masato, Tsujitani, Shun-ichi, Nagaya, Masaki, Yonemitsu, Yoshikazu
• Format: Article
• Language: English
• ISSN: 0008-5472; 1538-7445
• DOI: 10.1158/1538-7445.AM2014-2813

Purpose: Dendritic cell (DC)-based cancer vaccine may have a significant benefit to patients with advanced pancreatic cancer. However, variations among clinical studies make it hard to detect its clinical outcome. Here we statistically identified factors determining the clinical benefit using data obtained at seven Japanese institutions that employed the same DC preparation and treatment regimen. Patients and Methods: Among the 354 patients who met the inclusion criteria, 255 patients who received standard chemotherapy combined with peptide-pulsed DC vaccines were analyzed. Results: The mean survival time from diagnosis was 16.5 months (95%CI=14.4-18.5), and that from the first vaccination was 9.9 months (95%CI=8.0-12.9). Known prognostic baseline factors related to advanced pancreatic cancer, namely ECOG-PS, peritoneal metastasis, liver metastasis, and prognostic nutrition index (PNI) were also representative. Importantly, erythema reaction after vaccination was an independent and treatment-related predictive factor for better survival, and that OK432 might be a good adjuvant enhancing the antitumor immunity during DC vaccination. Conclusion: This is the first report of a multicenter clinical study suggesting the feasibility and possible clinical benefit of an add-on DC vaccine in patients with advanced pancreatic cancer who are undergoing chemotherapy. These findings need to be addressed in well-controlled prospective randomized trials. Citation Format: Masanori Kobayashi, Shimodaira Shigetaka, Kazuhiro Nagai, Masahiro Ogasawara, Hidenori Takahashi, Hirofumi Abe, Mitsugu Tanii, Masato Okamoto, Shun-ichi Tsujitani, Masaki Nagaya, Yoshikazu Yonemitsu, The DC vaccine study group of Japan Society of Innovative Cell Therapy (J-SICT). Survival benefit of an add-on dendritic cell vaccine for patients with inoperable pancreatic cancer receiving chemotherapy: a multicenter study. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 2813. doi:10.1158/1538-7445.AM2014-2813